This application proposes the Phase II COBRE continuation of the Vermont Center for Immunology and Infectious Diseases (VCIID) at the University of Vermont (UVM). During the Phase I COBRE period we created a multidisciplinary group of scientists and clinicians undertaking collaborative research in microbial pathogenesis and the immune response to infections. The keystone of Phase I was to achieve scientific excellence while building a critical mass of investigators in a vibrant and rigorous atmosphere. A significant component of this was the mentoring of 5 original junior faculty, all of whom obtained extramural funding, had numerous publications and awards, and 4 of 5 have been promoted. We also recruited 5 additional junior faculty in the final two years of Phase I. Already 4 of these 5 new faculty have obtained some extramural funding. In addition, the VCIID-COBRE provided support for cores in Genome Technologies/Bioinformatics, Proteomics, a seminar series of outside experts, a weekly Research-in- Progress forum, retreats, pilot project funding, and workshops on scientific issues, grant writing, and career development. As a result of these programs the VCIID grew during Phase I from 9 founding faculty to 21 faculty in 8 departments in 4 colleges, with 213 publications (49 from junior faculty), $47,694,003 in funding, without the COBRE ($8,818,374 from junior faculty), and recognition by the UVM College of Medicine as one of the five Centers of Excellence. During Phase II we will continue several of the above successful programs but modify them toward directing the faculty toward becoming a highly interactive group in a mature Center with collaborative grants and sustainability. The new 5 junior faculty will continue their projects for 1-4 additional years. Two senior faculty we be recruited to fill gaps in our intellectual repertoire, one in mucosal immunology to enhance our new Vaccine Trials Center, and the second in chronic infection/inflammation-induced cancer to broaden our thinking to the implications of chronic infectious conditions. Cores will be continued in Genome Technologies/Bioinformatics and Proteomics, with the addition of a new BSL3 facility core to accommodate the growing needs of VCIID investigators desiring to study BSL3 agents. Also in this area, we will form a unique partnership among the VCIID, UVM, and the Vermont Department of Health in which the State will build a new Department of Health laboratory building on the UVM campus attached to our research building containing the BSL3 facility. This will provide space for an expanded joint BSL3 facility to include animal and select agent use. These endeavors will position us to be competitive for new POI and U19 category grants.

Public Health Relevance

The VCIID has become one of five Centers of Excellence in the College of Medicine. It is a scientific and economic engine in Vermont, with 21 faculty examining the host response to viral, bacterial, and parasitic, infections, which cause significant morbidity and mortality throughout the world. The inflammatory processes during these infections are also relevant to autoimmunity and cancer. Our Vaccine Trials Center and partnership with the Vermont Department of Health provide a translational medicine and public health role.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Exploratory Grants (P20)
Project #
8P20GM103496-07
Application #
8304225
Study Section
Special Emphasis Panel (ZRR1-RI-B (01))
Program Officer
Liu, Yanping
Project Start
2006-08-01
Project End
2016-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
7
Fiscal Year
2012
Total Cost
$2,258,504
Indirect Cost
$777,518
Name
University of Vermont & St Agric College
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
066811191
City
Burlington
State
VT
Country
United States
Zip Code
05405
Ubags, Niki D J; Stapleton, Renee D; Vernooy, Juanita H J et al. (2016) Hyperleptinemia is associated with impaired pulmonary host defense. JCI Insight 1:
Kevorkian, Yuzo; Shirley, David J; Shen, Aimee (2016) Regulation of Clostridium difficile spore germination by the CspA pseudoprotease domain. Biochimie 122:243-54
Ather, Jennifer L; Burgess, Edward J; Hoyt, Laura R et al. (2016) Uricase Inhibits Nitrogen Dioxide-Promoted Allergic Sensitization to Inhaled Ovalbumin Independent of Uric Acid Catabolism. J Immunol 197:1720-32
Massilamany, Chandirasegaran; Koenig, Andreas; Reddy, Jay et al. (2016) Autoimmunity in picornavirus infections. Curr Opin Virol 16:8-14
Champagne, Devin P; Hatle, Ketki M; Fortner, Karen A et al. (2016) Fine-Tuning of CD8(+) T Cell Mitochondrial Metabolism by the Respiratory Chain Repressor MCJ Dictates Protection to Influenza Virus. Immunity 44:1299-311
Nielsen, Brian W; Bonney, Elizabeth A; Pearce, Bradley D et al. (2016) A Cross-Species Analysis of Animal Models for the Investigation of Preterm Birth Mechanisms. Reprod Sci 23:482-91
Willsey, Graham G; Wargo, Matthew J (2016) Sarcosine Catabolism in Pseudomonas aeruginosa Is Transcriptionally Regulated by SouR. J Bacteriol 198:301-10
Collins, Cheryl C; Bashant, Kathleen; Erikson, Cuixia et al. (2016) Necroptosis of Dendritic Cells Promotes Activation of γδ T Cells. J Innate Immun 8:479-92
Ather, Jennifer L; Chung, Michael; Hoyt, Laura R et al. (2016) Weight Loss Decreases Inherent and Allergic Methacholine Hyperresponsiveness in Mouse Models of Diet-Induced Obese Asthma. Am J Respir Cell Mol Biol 55:176-87
Krishnamurthy, Shruthi; Deng, Bin; Del Rio, Roxana et al. (2016) Not a Simple Tether: Binding of Toxoplasma gondii AMA1 to RON2 during Invasion Protects AMA1 from Rhomboid-Mediated Cleavage and Leads to Dephosphorylation of Its Cytosolic Tail. MBio 7:

Showing the most recent 10 out of 124 publications